ZA200806563B - Double helical oligonucleotides interfering with mRNA used as effective anticancer agent - Google Patents

Double helical oligonucleotides interfering with mRNA used as effective anticancer agent

Info

Publication number
ZA200806563B
ZA200806563B ZA200806563A ZA200806563A ZA200806563B ZA 200806563 B ZA200806563 B ZA 200806563B ZA 200806563 A ZA200806563 A ZA 200806563A ZA 200806563 A ZA200806563 A ZA 200806563A ZA 200806563 B ZA200806563 B ZA 200806563B
Authority
ZA
South Africa
Prior art keywords
anticancer agent
double helical
effective anticancer
mrna used
interfering
Prior art date
Application number
ZA200806563A
Other languages
English (en)
Inventor
Wieczorek Maciej
Wietrzyk Joanna
Nasulewicz Anna
Szczaurska Katarzyna
Guzenda Piotr Jan
Lamparska-Przybysz Monika
Original Assignee
Celon Pharma Sp Z O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celon Pharma Sp Z O O filed Critical Celon Pharma Sp Z O O
Publication of ZA200806563B publication Critical patent/ZA200806563B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ZA200806563A 2006-01-31 2008-07-28 Double helical oligonucleotides interfering with mRNA used as effective anticancer agent ZA200806563B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL378857A PL378857A1 (pl) 2006-01-31 2006-01-31 Podwójnie skręcone oligonukleotydy interferujące z mRNA genu WNT1 (siRNA) stosowane w celu hamowania poliferacji komórek nowotworowych

Publications (1)

Publication Number Publication Date
ZA200806563B true ZA200806563B (en) 2009-07-29

Family

ID=38327790

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200806563A ZA200806563B (en) 2006-01-31 2008-07-28 Double helical oligonucleotides interfering with mRNA used as effective anticancer agent

Country Status (8)

Country Link
US (1) US20090264510A1 (xx)
EP (1) EP1984498A2 (xx)
CN (1) CN101421398A (xx)
AU (1) AU2007210325A1 (xx)
CA (1) CA2640082A1 (xx)
PL (1) PL378857A1 (xx)
WO (1) WO2007089161A2 (xx)
ZA (1) ZA200806563B (xx)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL388513A1 (pl) 2009-07-12 2011-01-17 Celon Pharma Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie oligonukleotydu siRNA
CN107090456B (zh) * 2010-08-02 2022-01-18 瑟纳治疗公司 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制
CN102380099A (zh) * 2011-06-15 2012-03-21 中山大学肿瘤防治中心 Wnt2在制备抑制食管癌的药物的应用
CN107365771B (zh) * 2016-08-18 2020-11-10 广州市锐博生物科技有限公司 用于抑制CTNNB1靶基因mRNA表达的寡核酸分子及其成套组合物
CN114464259B (zh) * 2022-01-14 2024-03-29 郑州大学 一种靶向PD-1 mRNA反义脱氧寡核苷酸的筛选方法及应用
CN116825199A (zh) * 2023-02-21 2023-09-29 王全军 筛选siRNA序列以降低脱靶效应的方法及系统

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
WO2003012052A2 (en) * 2001-07-30 2003-02-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Specific inhibition of gene expression by small double stranded rnas
GB0328928D0 (en) * 2003-12-12 2004-01-14 Cancer Rec Tech Ltd Materials and methods relating to cell cycle control
AU2005248351A1 (en) * 2004-05-14 2005-12-08 The Regents Of The University Of California Methods for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA

Also Published As

Publication number Publication date
WO2007089161A2 (en) 2007-08-09
CN101421398A (zh) 2009-04-29
US20090264510A1 (en) 2009-10-22
AU2007210325A1 (en) 2007-08-09
WO2007089161A3 (en) 2008-04-03
CA2640082A1 (en) 2007-08-09
EP1984498A2 (en) 2008-10-29
PL378857A1 (pl) 2007-08-06

Similar Documents

Publication Publication Date Title
EP1996182A4 (en) CANCER TREATMENT WITH GAMMA SECRETASE INHIBITORS
EP1985891A4 (en) REDUCING GEAR
IL194007A0 (en) Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
SG10201406016SA (en) Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
EP2092892A4 (en) ultrasonograph
ZA200900038B (en) Liquid hardening
HK1138322A1 (zh) 羥甲基取代的 寡核苷酸和 複合物
EP2014237A4 (en) ULTRASOUND
EP2068038A4 (en) GEAR UNIT
EP2034219A4 (en) REDUCING GEAR
EP1988290A4 (en) GEAR PUMP
GB0821457D0 (en) Oligonucleotides
EP1997436A4 (en) ultrasonograph
GB0619182D0 (en) Oligonucleotide arrays
IL195773A0 (en) Polynucleotide therapy
EP2068036A4 (en) REDUCING GEAR
ZA200807960B (en) Catalyst composition
ZA200806563B (en) Double helical oligonucleotides interfering with mRNA used as effective anticancer agent
EP2062892A4 (en) AGENT ENHANCING HYPERTENSION
EP1986635A4 (en) ANTI CANCER AGENTS
EP2060233A4 (en) ULTRASOUND
EP2030629A4 (en) AGENT FOR IMPROVING LIPID METABOLISM
PT2154144E (pt) Oligonucleotídeos e utilização dos mesmos
EP2086591A4 (en) EFFICIENT NUCLEAR DISTRIBUTION OF ANTISENSE OLIGONUCLEOTIDES
EP2060263A4 (en) AGENT FOR IMPROVING LIPID METABOLISM